Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells

Engineering advanced logic and distributed computing in human CAR immune cells

(2021) Jang Hwan Cho et al.   Nature Communications

Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors

(2021) Jason J Luke et al.   Journal for ImmunoTherapy of Cancer

Anti-Mesothelin CAR T cell therapy for malignant mesothelioma

(2021) Laura Castelletti et al.   Biomarker Research

Targeting loss of heterozygosity for cancer-specific immunotherapy

(2021) Michael S. Hwang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Potent, Selective CARs as Potential T-Cell Therapeutics for HPV-positive Cancers

(2021) Xueyin Wang et al.   JOURNAL OF IMMUNOTHERAPY

A profile on the FoundationFocus CDxBRCA tests

(2020) Lindsey Ford et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Pan-cancer analysis of whole genomes

(2020)   NATURE

Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution

(2020) Saioa López et al.   NATURE GENETICS

Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data

(2020) Gils Roex et al.   Pharmaceutics

Structure-function relationships of chimeric antigen receptors in acute T cell responses to antigen

(2020) Han Xu et al.   MOLECULAR IMMUNOLOGY

Engineered T cells directed at tumors with defined allelic loss

(2020) Agnes E. Hamburger et al.   MOLECULAR IMMUNOLOGY

Discriminatory Power of Combinatorial Antigen Recognition in Cancer T Cell Therapies

(2020) Ruth Dannenfelser et al.   Cell Systems

Coordinating Cytoskeleton and Molecular Traffic in T Cell Migration, Activation, and Effector Functions

(2020) Marta Mastrogiovanni et al.   Frontiers in Cell and Developmental Biology

Clinical validation of the tempus xT next-generation targeted oncology sequencing assay

(2019) Nike Beaubier et al.   Oncotarget

Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent.

(2019) Prasad S. Adusumilli et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial

(2018) Gregory L. Beatty et al.   GASTROENTEROLOGY

Cytokine release syndrome

(2018) Alexander Shimabukuro-Vornhagen et al.   Journal for ImmunoTherapy of Cancer

Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancers

(2017) Mark H O’Hara et al.   Immunotherapy

Possible Compartmental Cytokine Release Syndrome in a Patient With Recurrent Ovarian Cancer After Treatment With Mesothelin-targeted CAR-T Cells

(2017) Janos L. Tanyi et al.   JOURNAL OF IMMUNOTHERAPY

Mesothelin Immunotherapy for Cancer: Ready for Prime Time?

(2016) Raffit Hassan et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen

(2014) Raffit Hassan et al.   CANCER

Evolution of acquired resistance to anti-cancer therapy

(2014) Jasmine Foo et al.   JOURNAL OF THEORETICAL BIOLOGY

Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody-Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect

(2014) S. Golfier et al.   MOLECULAR CANCER THERAPEUTICS

Six-locus high resolution HLA haplotype frequencies derived from mixed-resolution DNA typing for the entire US donor registry

(2013) Loren Gragert et al.   HUMAN IMMUNOLOGY

PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses

(2013) V. D. Fedorov et al.   Science Translational Medicine

Forward light scatter is a simple measure of T-cell activation and proliferation but is not universally suited for doublet discrimination

(2011) Ralph M. Böhmer et al.   CYTOMETRY PART A

Mathematical Modeling of Chimeric TCR Triggering Predicts the Magnitude of Target Lysis and Its Impairment by TCR Downmodulation

(2010) S. E. James et al.   JOURNAL OF IMMUNOLOGY

The landscape of somatic copy-number alteration across human cancers

(2010) Rameen Beroukhim et al.   NATURE

A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity

(2009) Y. Feng et al.   MOLECULAR CANCER THERAPEUTICS